50,000 New Drug Tests Among Brexit Worries for Pharma Companies

Global drugmakers from Johnson & Johnson to AstraZeneca Plc warned that potential trade and regulatory hurdles may burden them with a host of additional costs after Britain leaves the European Union.

In written testimony released in advance of a U.K. government committee hearing, pharmaceutical companies called for continued ease of access to the EU market and action to ensure they don’t face restrictive tariffs, delays at ports and divergent rules after Brexit. Others raised concerns about a possible departure of skilled workers and a blow to the country’s reputation as an attractive place to carry out research.